145 related articles for article (PubMed ID: 23649338)
1. Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation.
Uchida M; Ikesue H; Miyamoto T; Kato K; Suetsugu K; Ichinose K; Hiraiwa H; Sakurai A; Takenaka K; Muta T; Iwasaki H; Teshima T; Shiratsuchi M; Egashira N; Akashi K; Oishi R
Biol Pharm Bull; 2013; 36(5):819-24. PubMed ID: 23649338
[TBL] [Abstract][Full Text] [Related]
2. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy.
Uchida M; Ikesue H; Kato K; Ichinose K; Hiraiwa H; Sakurai A; Takenaka K; Iwasaki H; Miyamoto T; Teshima T; Egashira N; Akashi K; Oishi R
Am J Health Syst Pharm; 2013 Feb; 70(4):343-9. PubMed ID: 23370141
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation.
Uchida M; Kato K; Ikesue H; Ichinose K; Hiraiwa H; Sakurai A; Muta T; Takenaka K; Iwasaki H; Miyamoto T; Teshima T; Shiratsuchi M; Suetsugu K; Nagata K; Egashira N; Akashi K; Oishi R
Pharmacotherapy; 2013 Sep; 33(9):893-901. PubMed ID: 23712662
[TBL] [Abstract][Full Text] [Related]
4. Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
Fujiwara S; Terai Y; Tsunetoh S; Sasaki H; Kanemura M; Ohmichi M
J Gynecol Oncol; 2015 Oct; 26(4):311-9. PubMed ID: 26197776
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy.
Jordan K; Kinitz I; Voigt W; Behlendorf T; Wolf HH; Schmoll HJ
Eur J Cancer; 2009 May; 45(7):1184-1187. PubMed ID: 19135359
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of antiemesis effects of granisetron, aprepitant and dexamethasone to palonosetron, aprepitant and dexamethasone in treatment of high-emetic risk chemotherapy-induced nausea and vomiting - a retrospective study for efficacy and safety in a single institute].
Osawa H; Goto H; Myojo T
Gan To Kagaku Ryoho; 2013 May; 40(5):617-21. PubMed ID: 23863585
[TBL] [Abstract][Full Text] [Related]
9. Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
Cabanillas Stanchi KM; Vek J; Schlegel P; Rupprecht JV; Flaadt T; Weber S; Michaelis S; Lang P; Handgretinger R; Döring M
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1089-1100. PubMed ID: 32056007
[TBL] [Abstract][Full Text] [Related]
10. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
Hesketh PJ; Grunberg SM; Gralla RJ; Warr DG; Roila F; de Wit R; Chawla SP; Carides AD; Ianus J; Elmer ME; Evans JK; Beck K; Reines S; Horgan KJ;
J Clin Oncol; 2003 Nov; 21(22):4112-9. PubMed ID: 14559886
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy.
Kumagai H; Kusaba H; Yamanaka T; Nio K; Inadomi K; Takayoshi K; Ito M; Tamura S; Makiyama A; Makiyama C; Hirano G; Shibata Y; Shirakawa T; Mitsugi K; Ariyama H; Esaki T; Akashi K; Baba E
Medicine (Baltimore); 2018 Jun; 97(25):e11042. PubMed ID: 29923992
[TBL] [Abstract][Full Text] [Related]
12. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial.
Schmitt T; Goldschmidt H; Neben K; Freiberger A; Hüsing J; Gronkowski M; Thalheimer M; Pelzl le H; Mikus G; Burhenne J; Ho AD; Egerer G
J Clin Oncol; 2014 Oct; 32(30):3413-20. PubMed ID: 25225424
[TBL] [Abstract][Full Text] [Related]
13. Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Oyama K; Fushida S; Kaji M; Takeda T; Kinami S; Hirono Y; Yoshimoto K; Yabushita K; Hirosawa H; Takai Y; Nakano T; Kimura H; Yasui T; Tsuneda A; Tsukada T; Kinoshita J; Fujimura T; Ohta T
J Gastroenterol; 2013 Nov; 48(11):1234-41. PubMed ID: 23338487
[TBL] [Abstract][Full Text] [Related]
14. Palonosetron versus Granisetron in Combination with Aprepitant and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy: A Single-Institutional Retrospective Cohort Study.
Miyoshi T; Miyashita H; Matsuo N; Odawara M; Hori M; Hiraki Y; Kawanaka H
Biol Pharm Bull; 2021; 44(10):1413-1418. PubMed ID: 34602550
[TBL] [Abstract][Full Text] [Related]
15. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
16. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Jordan K; Jahn F; Jahn P; Behlendorf T; Stein A; Ruessel J; Kegel T; Schmoll HJ
Bone Marrow Transplant; 2011 Jun; 46(6):784-9. PubMed ID: 20838387
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
[TBL] [Abstract][Full Text] [Related]
18. Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.
Araz M; Karaagac M; Korkmaz L; Koral L; Inci F; Beypinar I; Uysal M; Artac M
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1091-1097. PubMed ID: 30963213
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
Miura S; Watanabe S; Sato K; Makino M; Kobayashi O; Miyao H; Iwashima A; Okajima M; Tanaka J; Tanaka H; Kagamu H; Yokoyama A; Narita I; Yoshizawa H
Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
[TBL] [Abstract][Full Text] [Related]
20. Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Suzuki S; Karayama M; Inui N; Kuroishi S; Fujisawa T; Enomoto N; Nakamura Y; Yokomura K; Toyoshima M; Imokawa S; Asada K; Masuda M; Yamada T; Watanabe H; Hayakawa H; Suda T
Med Oncol; 2016 Jul; 33(7):65. PubMed ID: 27235141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
